The US State of New Hampshire has announced that it will appeal a federal trial court decision, that a state law which banned firms from "data mining" by selling, using or distributing patients' prescription drug information, was unconstitutional. Federal Judge Paul Barbadoro ruled that the law violates the the US Constitution's First Amendment and "restricts constitutionally protected speech."
New Hampshire Governor John Lynch (Democrat) approved legislation last year that made New Hampshire the first state to restrict drugmakers from having access to information that identifies physicians' prescribing choices.
IMS Health and Verispan, two of the major US analysts of medical data, filed a complaint in a US District Court. The plaintiffs said the law "violated free speech rights, endangered public health and impeded research." The New Hampshire case was that: "our primary argument was that the transmission of data was not speech."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze